全文获取类型
收费全文 | 249篇 |
免费 | 13篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 15篇 |
妇产科学 | 2篇 |
基础医学 | 18篇 |
口腔科学 | 4篇 |
临床医学 | 18篇 |
内科学 | 56篇 |
皮肤病学 | 2篇 |
神经病学 | 6篇 |
特种医学 | 42篇 |
外科学 | 70篇 |
综合类 | 1篇 |
一般理论 | 1篇 |
预防医学 | 7篇 |
眼科学 | 1篇 |
药学 | 6篇 |
肿瘤学 | 14篇 |
出版年
2023年 | 1篇 |
2021年 | 1篇 |
2018年 | 3篇 |
2016年 | 3篇 |
2015年 | 2篇 |
2014年 | 4篇 |
2013年 | 4篇 |
2012年 | 9篇 |
2011年 | 3篇 |
2010年 | 8篇 |
2009年 | 7篇 |
2008年 | 8篇 |
2007年 | 16篇 |
2006年 | 8篇 |
2005年 | 3篇 |
2004年 | 2篇 |
2003年 | 5篇 |
2002年 | 7篇 |
2001年 | 7篇 |
2000年 | 5篇 |
1999年 | 7篇 |
1998年 | 10篇 |
1997年 | 11篇 |
1996年 | 14篇 |
1995年 | 14篇 |
1994年 | 11篇 |
1993年 | 12篇 |
1992年 | 7篇 |
1991年 | 16篇 |
1990年 | 3篇 |
1989年 | 7篇 |
1988年 | 8篇 |
1987年 | 2篇 |
1986年 | 2篇 |
1985年 | 3篇 |
1983年 | 3篇 |
1982年 | 7篇 |
1981年 | 5篇 |
1980年 | 6篇 |
1977年 | 4篇 |
1976年 | 1篇 |
1975年 | 4篇 |
排序方式: 共有263条查询结果,搜索用时 15 毫秒
41.
42.
43.
R Schlick M Djamilian W de Riese M Truss E P Allhoff U Jonas 《Der Urologe. Ausg. A》1992,31(4):238-242
One of the most dramatic dangers in treating nephrolithiasis by ESWL is the development of intra- and perirenal bleeding, which requires therapeutic intervention. Even in patients whose blood parameters suggest they are healthy, hematomas are found in up to 80%. Therefore, ESWL must be regarded as contraindicated in patients with blood disorders. A case of a patient suffering from hemophilia B and from a large renal pelvic stone is reported, whom we treated by ESWL twice after sufficient substitution. X-ray revealed that the patient was stone-free on the 25th day after the first ESWL session. ESWL. A review of the literature is presented. 相似文献
44.
The low energy and short range of 55-Fe Auger electrons were utilized in mice to deliver lethal intracellular radiation to iron-incorporating erythropoietic precursors with minimal radiation damage to other bone marrow cells. The ensuing intramedullary, selective erythropoietic death was demonstrated by absolute and differential bone marrow cell counts and by decreased blood uptake of 59-Fe. The decreased number of colony-forming units in spleen colony assay and the decreased ability of tranplanted bone marrow to protect fatally irradiated mice shows that the bone marrow was partially depleted of pluripotent stem cells. These data are interpreted to indicate an increased pluripotent stem cell utilization in response to increased demand for differentiation of stem cells along the erythropoietic pathway. 相似文献
45.
A survey was undertaken to examine the impact of Medicare's Prospective Payment System (PPS) and other recent changes in the health care environment on providers' decisions regarding acquisition of high-cost technologic equipment. The survey group included 199 hospitals and freestanding imaging centers known to have acquired magnetic resonance (MR) imaging units, as well as a random sample of 400 hospitals whose acquisition decisions were unknown to the authors. Fifty-eight percent of the known adopters and 61% of the randomly selected hospitals responded to the survey. Nonadopters' decisions were dominated by economic considerations, including the high cost of MR imagers and concerns about Medicare's reimbursement policies. Competition and a desire to provide the highest quality of care are counterbalancing the retardant effects of PPS, however, and are stimulating widespread diffusion of MR imagers. 相似文献
46.
47.
48.
49.
Klatte T Ittenson A Röhl FW Ecke M Allhoff EP Böhm M 《British journal of cancer》2006,95(9):1167-1173
We conducted a non-randomised controlled phase II trial to investigate the role of preoperative administration of interleukin-2 (IL-2) in patients with renal cell carcinoma undergoing tumour nephrectomy. A total of 120 consecutive patients were allocated alternately to the two study groups: perioperative immunomodulation with IL-2 (IL-2 group; n=60) and perioperative immunomonitoring without immunomodulation (control group; n=60). Patients from the IL-2 group received four doses of 10 x 10(6) IU m(-2) twice daily subcutaneously a week before operation followed by a daily maintenance dose of 3 x 10(6) IU m(-2) subcutaneously until a day before the operation. Parameters of cellular and humoral immunity (leucocytes, T-cell markers CD3, CD4, and CD8, B-cell marker CD19, monocyte marker CD14, natural killer (NK) cell markers CD16, CD56, and CD57, activation markers CD6, CD25, CD28, and CD69, progenitor cell marker CD34, as well as IL-2, IL-6, IL-10, soluble IL-2 receptor, IL-1 receptor antagonist, transforming growth factor-beta1, and vascular endothelial growth factor) were measured in peripheral venous blood at various intervals. Interleukin-2-related toxicity was WHO grade 1 (24%), 2 (67%), and 3 (9%). In the postoperative period, T-cell markers, activation markers, and NK cell markers decreased, and IL-6 and IL-10 increased. However, all these alterations were significantly less accentuated in patients who had been pretreated with IL-2. Median follow-up was 40 months. Tumour-specific survival in the IL-2 group and the control group was 98 vs 81% after 1 year and 86 vs 73% after 5 years (P=0.04). A similar effect was found for progression-free survival. We conclude that IL-2 can be safely administered in the perioperative period and modulates immunological parameters. However, to validate the survival data, a larger randomised phase III trial is needed. 相似文献
50.
Nelius T Klatte T Yap R Kalinski T Röpke A Filleur S Allhoff EP 《BJU international》2006,98(3):580-585
OBJECTIVE: To test the combination of docetaxel with two different doses of estramustine in patients with hormone-refractory prostate cancer (HRPC), to improve response rates and to lower side-effects, as docetaxel-based chemotherapy is an increasing option for men with advanced HRPC, and alone or combined with estramustine, docetaxel improves median survival. PATIENTS AND METHODS: In all, 72 patients with metastatic HRPC were randomly assigned to receive docetaxel (70 mg/m(2) intravenously, on day 2 every 21 days) and estramustine (3 x 280 mg/day oral starting 1 day before docetaxel, for 5 consecutive days) for arm A, or estramustine (3 x 140 mg/day oral starting 1 day before docetaxel, for 3 consecutive days) for arm B. Premedication with oral dexamethasone at a total daily dose of 16 mg, in divided doses twice a day was administered in arm A on day 1-5 and in arm B on day 1-3. Initially, six cycles were administered. Chemotherapy was restarted after a significant increase in prostate-specific antigen (PSA) level. Patients were monitored for any measurable PSA response and toxicity. RESULTS: Between the arms there was no statistically significant difference in time to progression and overall survival. However, treatment B had less treatment-related toxicity than A. Independent prognostic variables were baseline factors like PSA level, haemoglobin level, Eastern Cooperative Oncology Group performance status, and bone pain at presentation. CONCLUSIONS: In this randomized phase II study the combination of docetaxel and estramustine had substantial activity in HRPC, with a significant incidence of severe toxicity, both haematological and not. Nevertheless, treatment-related toxicity was predictable and manageable. There was no better effect with a higher dose of estramustine with docetaxel than for a lower dose. There was a slight tendency to higher toxicity for high-dose estramustine but this was not statistically significant. The present results support the assertion that estramustine is not necessary in docetaxel-based treatment regimens. 相似文献